Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for diabetic patients with multivessel coronary artery disease undergoing PCI or CABG
MOH_2018-10-02_003656Phase 4Not yet recruiting
- Sponsor
- פרופ' ירון ארבל
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of allopurinol in coronary arteriosclerosis, acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by פרופ' ירון ארבל. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
allopurinol
03
Conditions
coronary arteriosclerosisacute coronary syndrome (ACS)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2018-10-02_003656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-02_003656.